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Abstract-The intracellular action on exocytosis of botulinim A toxin and constituent chains was studied 
using permeabilized isolated nerve endings from the rat neural lobe. The release of the neuropeptide 
vasopressin was measured by radioimmunoassay. In the presence ofthe reducing agent dithiothreitol, the 
two-chain form of botulinum A toxin inhibited vasopressin release induced by 10 Jl M free calcium. Half 
maximal inhibition was obtained with 15 nM botulinum A toxin. In the absence of the heavy chain the 
light chain of the toxin strongly inhibited exocytosis with a half maximal effect of 2.5 nM. The inhibitory 
effects on secretion could be prevented by incubating the light chain with an immune serum against 
botulinum A toxin. The heavy chain of botulinum A toxin did not affect vasopressin release. However, 
it prevented the inhibitory effects of the light chain on stimulated exocytosis. 
It is concluded that botulinum A toxin inhibits the calcium-dependent step leading to exocytosis 
by interfering with a target present in the isolated and permeabilized nerve terminals. The functional 
domain of this neurotoxin, which is responsible for the inhibition of vasopressin release, is present in its 
light chain. 
Botulinum A toxin belongs to a family of cIosely 
reIated neurotoxins. The 150,000 mol. wt protein con-
sists of a heavy chain (100,000 mol. wt) and a light 
chain (50,000 mol. wt) covalently linked by a disulfide 
bond. It inhibits neuro transmission at the peripheral 
cholinergic nerve endings by inhibiting neurotrans-
mitter release. A three-step model is thought to 
produce the paralytic effects. It consists of (i) extra-
cellular binding, (ii) internalization and (iii) intra-
cellular poisoning (cf. Refs 12 and 19). The toxins' 
effects are restricted to the nervous tissue when given 
extracellularly. However, an extracellular application 
does not allow the differentiation of the intracellular 
processes involved in the final inhibition of transmit-
ter release and the role played by the individual 
chains of the toxin. 
Recently, using cultured adrenal chromaffin cells 
permeabilized with streptolysin 0, it has been shown 
that intracellularly applied botulinum A toxin is more 
effective in the presence of a reducing agent. Indeed, 
the light chain of botulinum A toxin alone inhibited 
Ca2+ -stimulated catecholamine release.5,20,21 In con-
trast, both the heavy and the light chain must be 
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present in Aplysia neurons to inhibit transmitter 
release. 16 So far it is unknown whether these dis-
crepancies are due to a general difference in the 
exocytotic mechanism in neurons as compared to 
endocrine cells or to differences between molluscs and 
mammals. 
To address some of these questions, the nerve 
terminals isolated from the rat neural lobe were used as 
a mammalian neuronal system. These nerve endings 
represent a potent tool for studying the mechanism of 
stimulus-secretion coupling. 14 They can be success-
fully permeabilized with digitonin and addition of 
micromolar amounts of Ca2+ are then sufficient to 
elicit neurohormone release.9 This process requires 
magnesium and chloride ions but not exogenous 
A TP. IO The permeabilized nerve terminals survive 
even prolonged incubations and are therefore suitable 
for studies with the slowly acting neurotoxins. 
EXPERIMENTAL PROCEDURES 
Preparation 0/ isolated neurosecretory nerve terminals 
The neural lobes were isolated from male Wistar rats 
(Charles River, Sulzfeld, F.R.G.) weighing 250--300 g and 
washed with normal Locke saline containing (in mM): NaCI 
(140); KHC03 (5); MgCI2 (I); CaCI2 (2.2); Tris-HEPES (10); 
glucose (10); bovine serum albumin (Miles) 0.025%, 
pH 7.25. The medium was then replaced by a buffer contain-
ing 270 mM sucrose, 10 mM Tris-HEPES, 2 mM EGTA 
instead of 0.01 mM EGTA as described previously.8 
The nerve endings were then isolated as described8 with 
some minor modifications. Briefly, the neurohypophyses 
were homogenized in the buffered sucrose solution and 
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centrifuged at 100 g for Imin. The supernatant was taken 
and centrifuged again at 2400 g for 5 min. The 
pellet contains mostly isolated nerve endings as judged by 
electron microscopy.15 Throughout the isolation procedure 
and the experiment the temperature was maintained at 
37°C. The nerve endings were then resuspended in normal 
Locke solution and loaded onto 0.20 jlm Gelman filters 
(Acro, LC 13) and perfused as given below. 
Superfusion of the isolated nerve endings 
The isolated nerve endings were perfused by means of a 
multichannel peristaltic pump (Ismatec IPN 8) for 60 min 
with normal Locke at a flow rate of 50 jll/min which 
was then increased to 100 jll/min until the end of the 
experiment. The perfusion was further continued with 
normal Locke containing no Ca2+ but 5 mM EGT A for 
10 min. The medium was then replaced by K + -glutamate 
buffer (medium B) containing (in mM): K + -glutamate (130); 
MgCl2 (2); EGTA (5); glucose (10); PIPES [piperazine-
N,N'-bis(2-ethane sulfonic acid)] (20); bovine serum albu-
min 0.025%, pH 6.8 and perfusion-run for a further 30 min. 
For permeabilization, the nerve endings were perfused for 
5 min with IIlM digitonin in medium B. Subsequently, the 
terminals were perfused for 25 min with the various forms 
of botulinum A toxin dissolved in medium B supplemented 
with I mM dithiothreitol (DTT). Stimulation was per-
formed for 10 min with medium B supplemented with 
10 Il M free Ca2+. Collection of the perfusate by means of 
a ffaction collector (Gilson-203) started 130 min after load-
ing, i.e. 6 min before the Cal+ stimulation. Fractions were 
collected every 2 min and immediately frozen until radio-
immunoassay for released arginine vasopressin (A VP) was 
performed.1 The Ca2+ evoked hormone release was calcu-
la ted by subtracting the mean basal release determined in 
the fractions preceding the onset of the Ca2+ stimulus from 
the amount of hormone found in each of the following eight 
fractions. 8 Free Ca2+ concentrations were calculated using 
the stability constants listed 18 and measured with a Cal+-
sensitive electrode4 as described recently.11 
Materials 
Botulinum A toxin (two-chain form), as obtained from 
Batelle Institute, Frankfurt, F.R.G., was homogeneous on 
SDS gel electrophoresis. It was separated into its heavy and 
light chain by high performance liquid chromatography 
anion exchange chromatography using a modification of 
the low performance liquid chromatography procedure 
described. 17 All steps were performed at 18°C at pH 8.4 
(adjusted with NaOH). Typically 600 Ilg (I ml) botulinum A 
toxin was first desalted on a Econo-Pac IOGD (Bio-Rad) 
column and then applied to a Mono Q 5/5 (Pharmacia-
LKB) co!umn both equilibrated with buffer I containing 
(in mM): Na2 B.o7 (7.5) and NaH2 PO. (15). The Mono Q 
column was washed with 6 ml of buffer. For chain separ-
ation 50 mM DTT dissolved in 1.5 ml ofbuffer I was applied 
to the column and the fiow was stopped for 2 h. The light 
chain was then eJuted at a rate of 0.25 ml/min with 7.5 ml 
of a mixture of nine parts buffer II (buffer II supplemented 
with 2 M urea and 50 mM DTT) and one part of buffer III 
containing (in mM): Na2 B.01 (75); NaH2PO. (ISO); urea (2000); DTT (50). The absorbed heavy chain was finally 
eluted from the column with 7.5 ml of buffer IH. Fractions 
were collected and the chains were located using a protein 
assay.6 Immediately after separation the chains were 
dialysed against a K-glutamate buffer containing (in mM): 
K + -glutamate (J 50); PIPES (10); EGTA (0.5); nitrilotri-
acetic acid (5), pH 7.2 supplemented with I or 5 mM DTT. 
Toxicity (wso , s.c. in mice) was I ng/kg for the two-chain 
form and between land 5 jlgjkg for the separated heavy or 
light chains, respectively. Botulinum A antitoxin, an im-
mune serum from horse cg 750 lU/mi, was obtained from 
Behring Werke Marburg, F.R.G., and dialysed against 
K-glutamate buffer before use. 
RESULTS 
When added to permeabilized neurosecretory 
nerve terminals the two-chain form of botulinum A 
toxin decreased the Ca2+ -evoked vasopressin release 
within 25 min. Inhibition started at botulinum A 
toxin concentrations below 5 nM. The presence of a 
reducing agent, DTT, was required for the inhibitory 
effect of the two-chain form of botulinum A toxin. In 
the absence of DTT almost no inhibition occurred. 
Fifty per cent inhibition was achieved with around 
15 nM toxin (Fig. 1). 
The isolated light chain of botulinum A toxin 
alone is fully active in these permeabilized nerve 
endings (Fig. 2). Incubation for aperiod of 25 min 
in the absence of free Ca2+ reduced the basal 
release only slightly. However, compared to the con-
trols, the Ca2+ -induced AVP release was strongly 
inhibited by the botulinum A toxin. The permeabi-
lized terminals did not respond to a second Ca2+ 
challenge given after 50 min washout with Ca2+ -free 
solution. This indicates that the effect of botulinum 
A toxin light chain was irreversible. Under the 
same conditions the controls fully responded to Ca2+ 
(Fig. 2). 
The inhibitory effect of botulinum A toxin light 
chain on stimulated A VP release could be fully 
overcome by preincubating the light chain with 
an immune serum against botulinum A toxin, indicat-
ing its specific action. The antiserum itself did 
not interfere with the basal or evoked A VP release 
(Fig. 3). 
In order to find out whether the light chain alone 
is responsible for the observed effects or whether 
the heavy chain modifies the action of light chain, 
light and heavy chains were applied simultaneously. 
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Fig. 1. Dose-response curve of botulinum A toxin (two-
chain form) on evoked A VP release from permeabilized 
nerve terminals in the presence or absence of I mM DTT. 
Permeabilized nerve terminals were incubated for 25 min at 
3TC with various amounts ofbotulinum A two-chain form 
(abscissa) in the absence (0) or presence (e) of I mM DTT. 
Values are expressed as percentage of the AVP release 
evoked by 10 IlM Ca2+. The values obtained in the presence 
of botulinum A toxin are the mean of three exper-
iments ± S.E. The mean of Ca2+ -evoked release from six 
individual experiments is taken as 100% (1667 ± 185 pg 
A VP relased during Ca2+ stimulation). 
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Fig. 2. Time course of A VP secretion from digitonin permeabilized isolated nerve terminals in the presence 
or absence of the light chain of botulinum A toxin. The isolated nerve terminals were perfused with buffer 
(medium B). After permeabilization they were preincubated with or without 3.3 nM botulinum toxin A 
light chain for 25 min. The nerve endings were then challenged with 10 JJ M free Ca2+ for 10 min. After 
a 50 min washout in the absence of Ca2+ the nerve endings were challenged again with 10 JJM free Ca2+ 
for 10 min. The concentration of A VP was measured in each fraction (2 min). The cIosed circIes represent 
the hormone release from control preparations and the open circIes that from toxin-treated nerve 
terminals. Values are expressed as means ± S.E. of four experiments. 
Interestingly, the combined addition of the two 
chains either applied in equimolar concentrations 
(Fig. 4a) or with a ten-fold excess of the heavy chain 
(Fig. 4b) overcame the inhibitory action of 1 nM light 
chain (Fig. 4a,b). The heavy chain alone did not alter 
basal or evoked AVP release (Fig. 4a,b). This result 
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Fig. 3. Specificity of the inhibitory effect of botulinum A 
toxin light chain on stimulated A VP release from permeabi-
lized nerve terminals. The experimental procedure was the 
same as in Fig. 2. The permeabilized nerve terminals were 
either preincubated with buffer (A), or with buffer contain-
ing 7.4 IE/ml antitoxin, an immune serum from horse (B), 
or with 1.8 nM light chain (C) or 1.8 nM light chain plus 
7.4 IE/ml antitoxin (D) prior to the addition of 10 JJM 
Ca2+. The Ca2+ evoked A VP release (percentage of control) 
within 10 min (corresponding to the first challenge in Fig. 2) 
is given as the mean of four experiments ± S.E. One-
hundred per cent of vasopressin release (column A) is the 
mean of four individual experiments (613 ± 30 pg AVP 
release during Ca2+ stimulation). 
is in accordance with experiments performed with the 
two-chain form in the presence of DTT, where 1 nM 
botulinum A toxin did not inhibit A VP release 
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Fig. 4. Addition of botulinum A toxin heavy chain over-
comes the inhibitory action of light chain on the A VP 
release from permeabilized nerve terminals. Two sets of 
experiments were performed in the presence of 1 mM DTT 
as outlined in Fig. 3. In the left panel (a) the heavy and the 
light chain (each about 1 nM) were applied to the permeabi-
lized nerve terminals either alone or after previous combi-
nation. In the right panel (b) the same amount oflight chain 
(1 nM) but 10 nM heavy chain was used. The nerve termi-
nals have been incubated with medium B before stimulation 
(A), with the heavy chain (B), with the light chain (C), and 
with both the heavy and the light chain (0). Values rep-
resent the Ca2+ -evoked A VP release (percentage of control) 
of either two (a) or four ± S.E. (b) experiments. Note that 
under either condition the heavy chain does not change 
the stimulated A VP release, but overcomes the inhibitory 
action of the light chain. One-hundred per cent represents 
1180 pg A VP released during Ca2+ stimulation in (a), and 
445 ± 64 pg in (b). 
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Fig. 5. Dose-response curve of the inhibitory effect of 
botulinum A toxin light chain on stimulated A VP release 
from permeabilized nerve terminals. Permeabilized nerve 
terminals were preincubated with increasing amounts 
of botulinum A toxin light chain (abscissa) as in Fig. 1. 
Ca2+ -evoked A VP release is expressed as percentage of 
contro!. The values are expressed as the mean of three 
experiments ± S.E. The mean Ca2+ -evoked release from the 
six control experiments is taken as 100% (2249 ± 56 pg). 
(cf. Fig. I with Fig. 4). Thus, the heavy chain of 
botulinum A toxin does not contribute to the 
intracellular action of the light chain but rather 
inhibits it. 
Figure 5 gives the dose-response curve of the 
inhibitory action of the light chain of botulinum A 
toxin on evoked A VP release from permeabilized 
nerve terminals. The inhibition started below a 
light chain concentration of 1 nM. The evoked 
A VP release was inhibited by 50% after application 
of 2.5 nM light chain for 25 min preceding the 
stimulation (Fig. 5). 
Even higher doses of the light chain did not give 
complete inhibition of A VP release. This observation 
is in agreement with the situation seen in permeabi-
lized chromaffin cells. 21 
DISCUSSION 
The regulation of neurotransmitter release from 
mammalian synaptic terminals is poorly understood. 
Neurohypophysial nerve endings are an exception 
because they can be permeabilized and the intra-
terminal regulation of exocytosis can be analysed.9•14 
We have used them to investigate the mechanism 
of neurotoxin action focussing on clostridial neuro-
toxins. 12•19 Here we present the first report upon 
intracellular effects of botulinum A toxin in a mam-
malian neuron. 
We found that the two-chain form ofbotulinum A 
toxin is more effective in the presence of a reducing 
agent, suggesting that the disulfide bridge which links 
the heavy and the light chain has to be cleaved before 
exocytosis is inhibited. More importantly, the light 
chain alone is fully active and more potent in inhibit-
ing neurohormone release as compared to the re-
duced two-chain form. The action of botulinum A 
toxin in permeabilized nerve terminals is in line with 
recent observations on streptolysin 0 permeabilized 
bovine adrenal chrom affin cells.20.21 In these neuro-
endocrine cells reductive conditions enhance the 
inhibitory effect on catecholamine secretion of the 
two-chain form of botulinum A toxin. 20 Furthermore, 
the light chain alone is fully active.5.21 
The da ta also fit with a more general concept of 
clostridial neurotoxin processing. The primary gene 
product, a single chain form, has to be cleaved 
proteolytically and this is followed by a reduction of 
the interchain disulfide bond. As a consequence the 
light chain is activated. Recent results obtained with 
the closely related tetanus toxin in permeabilized 
adrenal chromaffin and pel2 cells are along this line. 
The single chain form is ineffective, the potency ofthe 
two-chain form is increased by a reducing agent and 
the light chain alone is fully inhibitory.I-3 
Once in a cytosolic compartment the heavy chain 
which may be necessary for internalization is no 
Ion ger required for full activity of the light chain. 
Moreover, if heavy and light chains are simul-
taneously present they are less active than the light 
chain alone. Again the situation resembles the one 
seen within chromaffin cells. Here the heavy chain 
does not change or rat her reduces the potency of 
the light chains of botulinum A toxin21 or tetanus 
toxin. ' 
By contrast, in invertebrate neurons, such as 
those of the buccal ganglia of Aplysia, the roles of the 
chains are different. When directly injected into the 
neuron the light chain of botulinum A toxin is not 
active on its own but requires the presence of a heavy 
chain. 16 The presence of both chains of botulinum A 
toxin is unique since the light chain of tetanus toxin 
alone inhibits neurotransmitter release in Aplysia 
neurons. 13 
The differences in botulinum A toxin action 
between Aplysia neurons and mammalian neuronal 
or chrom affin cells needs further investigation. One 
important difference to the mammalian systems is the 
high osmolarity of the medium required for studies 
with Aplysia neurons. Tilis might alter the confor-
mation of the light chain of botulinum A toxin or its 
target. The addition ofthe heavy chain may then help 
the light chain to become effective. However, it is not 
excluded that the exocytosis of the large granules 
from mammalian nerve terminals and that of small 
synaptic vesicles from Aplysia neurons is regulated 
differently. 
Taken together the da ta presented here and those 
already published suggest that botulinum A toxin by 
its light chain attacks a step during exocytosis which 
is common to mammalian neurons and chromaffin 
cells. The precise localization of its attack, probably 
the vesicular or the plasma membrane, remains to 
be found. 
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